Glucagon-like peptide 1 (GLP-1): A promising approach and a novel treatment for patients with type 2 diabetes

International Journal of Clinical Practice, Supplement

Volumn , Issue 138, 2003, Pages 45-52

  Nauck, Michael A ^a  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADRENALIN; ANTIDIABETIC AGENT; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; LIRAGLUTIDE; METFORMIN; NORADRENALIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFECT; ENZYME INHIBITION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INTESTINE MUCOSA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STOMACH EMPTYING; VOMITING;

EID: 4043048804     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes/Metab Rev 1992; 8: 149-177.
2. Nauck MA, Heimesaat MM, Ørskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
3. Brown JC. Gastric Inhibitory Polypeptide. Heidelberg: Springer-Verlag; 1982.
4. Nauck MA, Hoist JJ, Willms B. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 1997; 29: 411-416.
5. Hoist JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10: 229-235.
6. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
7. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912-917.
8. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
9. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-988.
10. Wettergren A. Glucagon-like peptide-1. Gastrointestinal function and possible mechanism of action. Dan Med Bull 2001; 48: 19-28.
11. Flint A, Raben A, Astrup A, Hoist JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
12. Gutzwiller JP, Drewe J, Goke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-1544.
13. Stoffers DA, Kieffer TJ, Hussain MA et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-748.
14. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.
15. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
16. Gerich JE. Abnormal glucagon secretion in type 2 (noninsulin-dependent) diabetes mellitus: Causes and consequences. In: Creutzfeldt W, Lefèbvre P, editors. Diabetes mellitus: Pathophysiology and therapy. Berlin, Heidelberg: Springer Verlag; 1989: pp. 127-133.
17. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
18. Rahier JRD, Ibrahim M, Channaoui K. Islet cell populations in obese subjects and Type 2 (non-insulin-dependent) diabetic patients (abstract). Diabetologia 1989; 32 (Suppl. 1): 532 A.
19. Butler AE, Janson J, Bonner-Weir S et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
20. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996; 19: 468-471.
21. Zander M, Madsbad S, Madsen JL, Hoist JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
22. Nauck MA, Kleine N, Ørskov C et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
23. Willms B, Werner J, Holst JJ et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
24. Creutzfeldt WO, Kleine N, Willms B et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type 1 diabetic patients. Diabetes Care 1996; 19: 580-586.
25. Rachman J, Gribble FM, Levy JC, Turner RC. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211.
26. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-1421.
27. Ritzel R, Ørskov C, Hoist JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic static properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725.
28. Deacon CF, Nauck MA, Toft-Nielsen M et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
29. Nauck MA, Weber I, Bach I et al. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients. Diabetic Med 1998; 15: 937-945.
30. Nauck MA, Wollschläger D, Werner J et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553.
31. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Hoist JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613.
32. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
33. Juhl CB, Hollingdal M, Sturis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429.
34. Matthews D, Madsbad S, Schmilz O, Langendorf KW, Jakobsen G. The long-acting GLP-1 derivative, NN2211, a new agent for the treatment of type 2 diabetes (abstract). Diabetes 2002; 51 (Suppl. 2): A 84.
35. Bridon DP, Thibaudeau K, L'Archeveque BP et al. The long-acting GLP-1 agonist CJC 1131 exhibits high potency and extended pharmacokinetics in vivo (abstract). Diabetes 2002; 51 (Suppl. 2): A 93.
36. Thibaudeau K, Smith DC, Jette L et al. Development and characterization of long-acting degradation resistant GLP-1-DAC compounds for the treatment of type 2 diabetes (abstract). Diabetes 2002; 50 (Suppl. 2): A 116.
37. Göke R, Fehmann HC, Linn T et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-19655.
38. Thorens B, Porret A, Buhler L et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678-1682.
39. Kolterman O, Gottlieb A, Prickett K, Gaines E, Young A. Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with Type 2 diabetes (abstract). Diabetes 2000; 49 (Suppl. 1): A 114.
40. Fineman MS, Bicsak T, Shen L et al. AC 2993 (synthetic exendin-4) added to existing metformin (MET) and/or sulfonylurea (SFU) treatment improved glycemic control in patients with type 2 diabetes (DM2) durign 28 days of treatment (abstract). Diabetes 2002; 51 (Suppl. 2): A 85.
41. Deacon CF, Highes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47: 764-769.
42. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50: 1588-1597.
43. Åhren B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.